TY - JOUR AU - Boumber, Yanis PY - 2018 TI - Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer JF - Journal of Thoracic Disease; Vol 10, No 8 (August 2018): Journal of Thoracic Disease Y2 - 2018 KW - N2 - Tumors avoid immune surveillance by inactivating various T-cell cytotoxic pathways that can promote cell death (1-3). Cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) are expressed primarily on cytotoxic T lymphocytes. In contrast, programmed death ligand 1 (PD-L1) is expressed on antigen-presenting lymphoid and non-lymphoid tissues, on tumor cells, and on virus-infected cells. UR - http://jtd.amegroups.com/article/view/23082